290 related articles for article (PubMed ID: 30546090)
1. Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.
Lan Q; Peyvandi S; Duffey N; Huang YT; Barras D; Held W; Richard F; Delorenzi M; Sotiriou C; Desmedt C; Lorusso G; Rüegg C
Oncogene; 2019 Apr; 38(15):2814-2829. PubMed ID: 30546090
[TBL] [Abstract][Full Text] [Related]
2. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
4. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
[TBL] [Abstract][Full Text] [Related]
5. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
6. Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
Touati N; Tryfonidis K; Caramia F; Bonnefoi H; Cameron D; Slaets L; Parker BS; Loi S
Eur J Cancer; 2017 Feb; 72():95-102. PubMed ID: 28027521
[TBL] [Abstract][Full Text] [Related]
7. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.
Bidwell BN; Slaney CY; Withana NP; Forster S; Cao Y; Loi S; Andrews D; Mikeska T; Mangan NE; Samarajiwa SA; de Weerd NA; Gould J; Argani P; Möller A; Smyth MJ; Anderson RL; Hertzog PJ; Parker BS
Nat Med; 2012 Aug; 18(8):1224-31. PubMed ID: 22820642
[TBL] [Abstract][Full Text] [Related]
8. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T
Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085
[TBL] [Abstract][Full Text] [Related]
9. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
Okines AF
Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
[TBL] [Abstract][Full Text] [Related]
13. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
14. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
[TBL] [Abstract][Full Text] [Related]
15. Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.
Legrier ME; Bièche I; Gaston J; Beurdeley A; Yvonnet V; Déas O; Thuleau A; Château-Joubert S; Servely JL; Vacher S; Lassalle M; Depil S; Tucker GC; Fontaine JJ; Poupon MF; Roman-Roman S; Judde JG; Decaudin D; Cairo S; Marangoni E
Br J Cancer; 2016 Jan; 114(2):177-87. PubMed ID: 26695443
[TBL] [Abstract][Full Text] [Related]
16. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
17. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
20. Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β.
Yoon N; Park MS; Shigemoto T; Peltier G; Lee RH
Cell Death Dis; 2016 Apr; 7(4):e2191. PubMed ID: 27077807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
